ClariTrial | Search Clinical Trials

Explore/cardiovascular heart disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

584 results for “cardiovascular heart disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 39

Recruiting

Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients

Phase 3Non-small Cell Lung CancerCardiovascular Complication

Multiple cardiovascular drugs related to "Golden Triangle"

Sun Yat-sen University524 participants1 site · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

SAPT Versus DAPT in Incomplete Revascularization After CABG

Phase 3Coronary Artery Disease

Ticagreloracetylsalicylic acid

Campus Bio-Medico University800 participants1 site · ItalyCompletes Aug 2021

Compare CT.gov Full analysis →

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Phase 3Multiple Myeloma

TeclistamabDaratumumabLenalidomide+2 more

Janssen Research & Development, LLC1,590 participants263 sites · United States, Australia, AustriaCompletes Apr 2031

Compare CT.gov Full analysis →

Recruiting

Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage

Phase 2Sub-arachnoid Haemorrhage

LevosimendanPlacebo

Assistance Publique - Hôpitaux de Paris30 participants1 site · FranceCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

Phase 3Diabete Type 2Cardiovascular Diseases

AspirinAspirin PlaceboColchicine+1 more

Montreal Heart Institute10,000 participants39 sites · Australia, Canada, DenmarkCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

HB-adMSCs for the Treatment of Crohn's Disease

Phase 2Crohn Disease (CD)

HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells0.9% sodium chloride

Hope Biosciences Research Foundation46 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

Phase 2HFpEFLVDDMyocardial Fibrosis

[ARNI + SGLTi + AMR][SGLTi + previously taken RAAS blocker]

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation50 participants1 site · RussiaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Phase 2Breast CancerHeart Failure

TrastuzumabPertuzumabTrastuzumab emtansine

Population Health Research Institute130 participants8 sites · Brazil, Canada, RussiaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

Phase 3Pulmonary HypertensionHeart Failure With Reduced Ejection FractionHypertension

Pulmonary arterial denervationGuideline-directed medical therapy (GDMT) for heart failure

Pulnovo Medical (Wuxi) Co., Ltd.264 participants1 site · ChinaCompletes Aug 2025

Compare CT.gov Full analysis →

Recruiting

The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk

Phase 3Cardiovascular DiseasesUric Acid

Allopurinol 200 mgOptional intervention

Poznan University of Medical Sciences1,116 participants1 site · PolandCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

Phase 2Myocardial InfarctionCoronary Artery BypassPercutaneous Coronary Intervention

RPE (usual care)GXT+THHR (intervention)

Baystate Medical Center320 participants2 sites · United StatesCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)

Phase 3Coronary Artery Disease(CAD)

XTR004

Sinotau Pharmaceutical Group395 participants5 sites · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)

Phase 2Congenital Diaphragmatic HerniaPulmonary Hypertension

Sildenafil Oral SuspensionPlacebo

University of Utah40 participants1 site · United StatesCompletes Mar 2026

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure

Phase 1Phase 2Heart Failure

EHM implantation

University Medical Center Goettingen53 participants3 sites · GermanyCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients

Phase 3STEMI

Dapagliflozin

Mohamed Nabil Elkholy120 participants1 site · EgyptCompletes Mar 2025

Compare CT.gov Full analysis →

1–15 of 584

Explore/cardiovascular heart disease

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

584 results for “cardiovascular heart disease” · Recruiting · Phase 3 · Phase 2

Page 1 of 39

Recruiting

Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients

Phase 3Non-small Cell Lung CancerCardiovascular Complication

Multiple cardiovascular drugs related to "Golden Triangle"

Sun Yat-sen University524 participants1 site · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

SAPT Versus DAPT in Incomplete Revascularization After CABG

Phase 3Coronary Artery Disease

Ticagreloracetylsalicylic acid

Campus Bio-Medico University800 participants1 site · ItalyCompletes Aug 2021

Compare CT.gov Full analysis →

Recruiting

Phase 3Multiple Myeloma

TeclistamabDaratumumabLenalidomide+2 more

Janssen Research & Development, LLC1,590 participants263 sites · United States, Australia, AustriaCompletes Apr 2031

Compare CT.gov Full analysis →

Recruiting

Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage

Phase 2Sub-arachnoid Haemorrhage

LevosimendanPlacebo

Assistance Publique - Hôpitaux de Paris30 participants1 site · FranceCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

Phase 3Diabete Type 2Cardiovascular Diseases

AspirinAspirin PlaceboColchicine+1 more

Montreal Heart Institute10,000 participants39 sites · Australia, Canada, DenmarkCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

HB-adMSCs for the Treatment of Crohn's Disease

Phase 2Crohn Disease (CD)

HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells0.9% sodium chloride

Hope Biosciences Research Foundation46 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF

Phase 2HFpEFLVDDMyocardial Fibrosis

[ARNI + SGLTi + AMR][SGLTi + previously taken RAAS blocker]

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation50 participants1 site · RussiaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Phase 2Breast CancerHeart Failure

TrastuzumabPertuzumabTrastuzumab emtansine

Population Health Research Institute130 participants8 sites · Brazil, Canada, RussiaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure

Phase 3Pulmonary HypertensionHeart Failure With Reduced Ejection FractionHypertension

Pulmonary arterial denervationGuideline-directed medical therapy (GDMT) for heart failure

Pulnovo Medical (Wuxi) Co., Ltd.264 participants1 site · ChinaCompletes Aug 2025

Compare CT.gov Full analysis →

Recruiting

The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk

Phase 3Cardiovascular DiseasesUric Acid

Allopurinol 200 mgOptional intervention

Poznan University of Medical Sciences1,116 participants1 site · PolandCompletes Jul 2028

Compare CT.gov Full analysis →

Recruiting

Improving Cardiac Rehabilitation Exercise Using Target Heart Rate Trial

Phase 2Myocardial InfarctionCoronary Artery BypassPercutaneous Coronary Intervention

RPE (usual care)GXT+THHR (intervention)

Baystate Medical Center320 participants2 sites · United StatesCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)

Phase 3Coronary Artery Disease(CAD)

XTR004

Sinotau Pharmaceutical Group395 participants5 sites · ChinaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)

Phase 2Congenital Diaphragmatic HerniaPulmonary Hypertension

Sildenafil Oral SuspensionPlacebo

University of Utah40 participants1 site · United StatesCompletes Mar 2026

Compare CT.gov Full analysis →

Recruiting

Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure

Phase 1Phase 2Heart Failure

EHM implantation

University Medical Center Goettingen53 participants3 sites · GermanyCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients

Phase 3STEMI

Dapagliflozin

Mohamed Nabil Elkholy120 participants1 site · EgyptCompletes Mar 2025

Compare CT.gov Full analysis →

1–15 of 584